News
GSK strikes deal with US to lower prescription drug costs & boost respiratory medicine access
GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
- By IPP Bureau
| December 22, 2025
Pharma powerhouse GSK has reached a landmark agreement with the US government to reduce the cost of prescription medicines for American patients, including its extensive respiratory portfolio used by more than 40 million Americans with asthma and COPD.
The deal fulfills all four actions outlined by President Trump in his July 31st letter. Under the agreement, GSK will cut prices on select Medicaid medicines and launch new products with pricing that balances affordability and the value of innovation in developed markets.
In a major boost for patients, GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%.
The agreement also strengthens the U.S. supply chain through the President’s Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). GSK will secure a reserve of albuterol, the active ingredient in many inhalers, ensuring continued access for Americans with chronic respiratory conditions.
The deal covers both GSK and ViiV Healthcare, providing clarity on the future U.S. pricing framework and exempting both companies from Section 232 tariffs for three years. Terms of the agreements remain confidential.
GSK CEO Emma Walmsley said: “Today’s announcement builds on GSK’s strong track record of increasing access and improving the affordability of its medicines worldwide, including an ongoing commitment to responsible pricing.
"GSK has been at the forefront of respiratory innovation for decades – helping millions of Americans prevent and treat chronic respiratory diseases such as asthma and COPD. Through this agreement, GSK will ensure patients have access to the current portfolio of respiratory medicines while bringing the next wave of innovation to American patients.”
This move complements GSK’s September 2025 announcement to invest more than $30 billion in U.S. R&D and manufacturing over the next five years, including $2 billion in new commitments for facilities, AI, and digital technologies, creating hundreds of high-skilled jobs.
,_Thyrocare.jpg)
